Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela MR, Gevers TJG, Beretta-Piccoli BT, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K. Kocheise L, et al. Front Immunol. 2024 Jan 24;15:1369747. doi: 10.3389/fimmu.2024.1369747. eCollection 2024. Front Immunol. 2024. PMID: 38327519 Free PMC article.
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K. Kocheise L, et al. Front Immunol. 2024 Jan 10;14:1326078. doi: 10.3389/fimmu.2023.1326078. eCollection 2023. Front Immunol. 2024. PMID: 38268921 Free PMC article.
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Joerg V, et al. Among authors: kocheise l. Hepatol Commun. 2023 Oct 27;7(11):e0302. doi: 10.1097/HC9.0000000000000302. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37889520 Free PMC article.
Positionspapier „Universitäre Karrierewege“.
Staudacher JJ, Backes M, Bettinger D, Blüthner E, Dietz-Fricke C, Dugic A, Fusco S, Garbe J, Goeser F, Guliyeva S, Hamesch K, Hollenbach M, Huber Y, Kasper P, Kocheise L, Langsch P, Leppkes M, Martens N, Mücke MM, Munker S, Murillo K, Nagl S, Sanoubara F, Sturm N, Stathopoulos P, Storck K, Sulzer S, Thiel-Bodenstaff A, Tran F, Wiessner JR, Willuweit K, Yaqubi K, Zeidler C, Schlosser S; für die universitäre JuGa. Staudacher JJ, et al. Among authors: kocheise l. Z Gastroenterol. 2023 Aug;61(8):997-999. doi: 10.1055/a-2116-6308. Epub 2023 Aug 11. Z Gastroenterol. 2023. PMID: 37567237 German. No abstract available.
IL-22BP controls the progression of liver metastasis in colorectal cancer.
Giannou AD, Kempski J, Zhang T, Lücke J, Shiri AM, Zazara DE, Belios I, Machicote A, Seeger P, Agalioti T, Tintelnot J, Sagebiel A, Tomczak M, Bauditz L, Bedke T, Kocheise L, Mercanoglu B, Fard-Aghaie M, Giorgakis E, Lykoudis PM, Pikouli A, Grass JK, Wahib R, Bardenhagen J, Brunswig B, Heumann A, Ghadban T, Duprée A, Tachezy M, Melling N, Arck PC, Stringa P, Gentilini MV, Gondolesi GE, Nakano R, Thomson AW, Perez D, Li J, Mann O, Izbicki JR, Gagliani N, Maroulis IC, Huber S. Giannou AD, et al. Among authors: kocheise l. Front Oncol. 2023 May 31;13:1170502. doi: 10.3389/fonc.2023.1170502. eCollection 2023. Front Oncol. 2023. PMID: 37324022 Free PMC article.
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
Boehmer DFR, Formisano S, de Oliveira Mann CC, Mueller SA, Kluge M, Metzger P, Rohlfs M, Hörth C, Kocheise L, Lichtenthaler SF, Hopfner KP, Endres S, Rothenfusser S, Friedel CC, Duewell P, Schnurr M, Koenig LM. Boehmer DFR, et al. Among authors: kocheise l. Sci Immunol. 2021 Jul 16;6(61):eabe2550. doi: 10.1126/sciimmunol.abe2550. Sci Immunol. 2021. PMID: 34272227
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S. Ruzicka M, et al. Among authors: kocheise l. Leukemia. 2020 Apr;34(4):1017-1026. doi: 10.1038/s41375-019-0639-x. Epub 2019 Nov 18. Leukemia. 2020. PMID: 31740809 Free PMC article.